Shorena Janelidze

Jul 28, 2024 | jamanetwork.com | Shorena Janelidze |Gemma Salvadó |Suzanne Schindler |Sebastian Palmqvist

Key PointsQuestion  Which plasma biomarkers are useful to predict future development of Alzheimer disease (AD)–related β-amyloid (Aβ) pathology in cognitively unimpaired individuals (CU) with low brain Aβ levels?

Jun 13, 2024 | medrxiv.org | Rik Ossenkoppele |Gemma Salvadó |Shorena Janelidze |Alexa Pichet Binette

R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics. He has given lectures in symposia sponsored by GE Healthcare and serves on advisory boards for Asceneuron and Bristol Myers Squibb. SP has acquired research support (for the institution) from ki elements / ADDF and Avid. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Esai, Lilly, and Roche.

Jul 18, 2023 | nature.com | Sebastian Palmqvist |Shorena Janelidze |Simone Baiardi |Oskar Hansson

AbstractThere is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients with cognitive impairment, especially when coexisting with Alzheimer’s disease (AD) pathology (amyloid-β and tau). Using a seed amplification assay, we analyzed cerebrospinal fluid for misfolded LB-associated α-synuclein in 883 memory clinic patients with mild cognitive impairment or dementia from the BioFINDER study.

Mar 29, 2023 | jamanetwork.com | Shorena Janelidze |Randall J. Bateman |Oskar Hansson

Key PointsQuestion  Is chronic kidney disease (CKD) associated with changes in plasma concentrations of phosphorylated tau biomarkers (ie, p-tau217 and p-tau181) and corresponding percent phosphorylated tau to unphosphorylated tau ratios (pT217/T217 and pT181/T181)? Findings  In this cross-sectional study including 473 participants from 2 independent cohorts, CKD was associated with increased plasma concentrations of p-tau217 and p-tau181.